Short answer
Monopar Therapeutics (MNPR) filed an 8-K current report with the SEC on May 29, 2026 reporting Item 7.01 (Regulation FD Disclosure). Monopar disclosed Phase 2 ALXN1840 results in Wilson disease at EASL International Liver Congress 2026.
Monopar Therapeutics 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Monopar disclosed Phase 2 ALXN1840 results in Wilson disease at EASL International Liver Congress 2026
- Study NCT04422431 evaluated liver pathology and clinical symptoms
- Presentation furnished as Exhibit 99.1, providing the detailed efficacy and safety data relevant to investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monopar Therapeutics 8-K filings
Get the next MNPR 8-K as it lands
Follow MNPR for push alerts, or ask the research agent what this filing means.